Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.50 |
| ▸ | WNT3A | P56704 | 4/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550609 | 0.75 | CTNNB1 (0.50) | CTNNB1WNT3AP2RX7GSK3BKMT2A | |
| SCHEMBL8744790 | 0.75 | P2RX7 (0.54) | CTNNB1WNT3AP2RX7ALDH1A1SMN1; SMN2 | |
| SCHEMBL882968 | 0.75 | CTNNB1 (0.50) | CTNNB1WNT3AP2RX7ALDH1A1SMN1; SMN2 | |
| SCHEMBL26743677 | 0.75 | APLNR (0.37) | GSK3BALDH1A1TRPA1MAPK1HIF1A | |
| Hydrochloric Acid SCHEMBL2819700 | 0.73 | P2RX7 (0.52) | CTNNB1WNT3AP2RX7ALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL27039764 | 0.73 | CTNNB1 (0.48) | CTNNB1WNT3AP2RX7GSK3BALDH1A1 | |
| SCHEMBL17820367 | 0.73 | ALOX15 (0.44) | GSK3BALDH1A1TRPA1MAPK1HIF1A | |
| SCHEMBL208041 | 0.73 | CES2 (0.59) | CTNNB1WNT3AGSK3BALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8564384 | 0.72 | CES2 (0.57) | CTNNB1WNT3AGSK3BALDH1A1SMN1; SMN2 | |
| SCHEMBL5159948 | 0.71 | P2RX7 (0.61) | CTNNB1WNT3AP2RX7ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1472260-A2 | THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1467999-A1 | OXOTHIENO[3,2-B]PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1458719-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20040110787-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| US-20030207877-A1 | Pyridoquinoxaline antivirals | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| WO-2003059912-A1 | OXOTHIENO (3, 2-B) PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003053971-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207877-A1 | Pyridoquinoxaline antivirals | IFNAR1, SARS1, ZC3HAV1 | CTNNB1 4812/4885WNT3A 3890/4885P2RX7 1127/4885 |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | CTNNB1 4702/4885WNT3A 3544/4885P2RX7 3871/4885 |
| US-20040110787-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | RPL35, ZC3HAV1, RPL5 | CTNNB1 4726/4885WNT3A 4245/4885P2RX7 4348/4885 |
| US-20040138449-A1 | Antiviral agents | IRF3, IFNAR1, EIF2AK2 | CTNNB1 4819/4885WNT3A 4159/4885P2RX7 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.